Driving under the influence (DUI) of psychoactive substances is an issue of paramount concern in both public health and the criminal justice system. It affects millions of Americans yearly, and while there is extensive research on DUI among...
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
The purpose of this resource guide is to share an overview of ROSC and illustrate how these systems are an integral part of the new health care environment. This guide will align the tenets of health care reform to the benefits, framework...
Chaque mois de septembre, la campagne du Mois de rétablissement vise à accroître la sensibilisation et la compréhension des troubles mentaux et de la toxicomanie et à célébrer les personnes qui se rétablissent.
Au fil des ans, le Mois du...
Le Centre national d’excellence pour le rétablissement sans tabac de la Substance Abuse and Mental Health Services Administration (SAMHSA) est maintenant ouvert aux demandes. Offrant jusqu’à 5 millions de dollars US la subvention peut être...
